BrightPath Biotherapeutics Co.Ltd. Statistics
Want to see JP:4594 full AI Analyst Report?
BrightPath Biotherapeutics Co.Ltd. (4594) Stock Statistics & Valuation Metrics
Total Valuation
BrightPath Biotherapeutics Co.Ltd. has a market cap or net worth of JPY 5.34B. The enterprise value is JPY 5.67B.
- Market Cap
- JPY 5.34B
- Enterprise Value
- JPY 5.67B
Share Statistics
BrightPath Biotherapeutics Co.Ltd. has 140,515,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 140,515,800
- Owned by Insiders
- ―
- Owned by Institutions
- ―
Financial Efficiency
BrightPath Biotherapeutics Co.Ltd.’s return on equity (ROE) is -0.55 and return on invested capital (ROIC) is -53.00%.
- Return on Equity (ROE)
- -0.55
- Return on Assets (ROA)
- -0.50
- Return on Invested Capital (ROIC)
- -53.00%
- Return on Capital Employed (ROCE)
- -0.53
- Revenue Per Employee
- 2,000
- Profits Per Employee
- -31.07M
- Employee Count
- 42
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of BrightPath Biotherapeutics Co.Ltd. is -2.97. BrightPath Biotherapeutics Co.Ltd.’s PEG ratio is 0.34.
- PE Ratio
- -2.97
- PS Ratio
- 85126.88
- PB Ratio
- 2.90
- Price to FCF
- 0.00
- Price to Operating Cash Flow
- 0.00
- PEG Ratio
- 0.34
Income Statement
In the last 12 months, BrightPath Biotherapeutics Co.Ltd. had revenue of 84.00K and earned -1.30B in profits. Earnings per share was -11.70.
- Revenue
- 84.00K
- Gross Profit
- 55.00K
- Operating Income
- -1.29B
- Pretax Income
- -1.30B
- Net Income
- -1.30B
- EBITDA
- -1.30B
- Earnings Per Share (EPS)
- -11.70
Cash Flow
In the last 12 months, operating cash flow was 0 and capital expenditures 0, giving a free cash flow of 0 billion.
- Operating Cash Flow
- 0
- Free Cash Flow
- 0
- Free Cash Flow per Share
- 0.00
Dividends & Yields
BrightPath Biotherapeutics Co.Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- 0.00%
- Earnings Yield
- -30.20%
Stock Price Statistics
- Beta
- 0.80
- 52-Week Price Change
- -38.71%
- 50-Day Moving Average
- 46.92
- 200-Day Moving Average
- 54.44
- Relative Strength Index (RSI)
- 34.47
- Average Volume (3m)
- 1.44M
Important Dates
BrightPath Biotherapeutics Co.Ltd. upcoming earnings date is Feb 05, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 13, 2026
- Next Earnings Date
- Feb 05, 2027
- Ex-Dividend Date
- ―
Financial Position
BrightPath Biotherapeutics Co.Ltd. as a current ratio of 15.83, with Debt / Equity ratio of 0.00%
- Current Ratio
- 15.83
- Quick Ratio
- 15.83
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.66
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, BrightPath Biotherapeutics Co.Ltd. has paid 2.42M in taxes.
- Income Tax
- 2.42M
- Effective Tax Rate
- -0.00
Enterprise Valuation
BrightPath Biotherapeutics Co.Ltd. EV to EBITDA ratio is -2.30, with an EV/FCF ratio of 0.00.
- EV to Sales
- 59629.71
- EV to EBITDA
- -2.30
- EV to Free Cash Flow
- 0.00
- EV to Operating Cash Flow
- 0.00
Balance Sheet
BrightPath Biotherapeutics Co.Ltd. has JPY 2.16B in cash and marketable securities with JPY 0.00 in debt, giving a net cash position of JPY 2.16B billion.
- Cash & Marketable Securities
- JPY 2.16B
- Total Debt
- JPY 0.00
- Net Cash
- JPY 2.16B
- Net Cash Per Share
- JPY 15.34
- Tangible Book Value Per Share
- JPY 17.80
Margins
Gross margin is 62.90%, with operating margin of -2575346.77%, and net profit margin of -2570440.32%.
- Gross Margin
- 62.90%
- Operating Margin
- -2575346.77%
- Pretax Margin
- -2566537.10%
- Net Profit Margin
- -2570440.32%
- EBITDA Margin
- -2594083.87%
- EBIT Margin
- -2594083.87%
Analyst Forecast
The average price target for BrightPath Biotherapeutics Co.Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -94.55%
- EPS Growth Forecast
- -6.51%
Scores
- Smart Score
- ―
- AI Score
- 44

